@article{95b4286ffa4b48098feb7b89984165c5,
title = "Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III",
abstract = "Bacillus Calmette-Guerin (BCG) remains the only FDA-approved first-line therapy in patients with high-risk non-muscle invasive bladder cancer. Recurrences, even after adequate BCG therapy, are common and the efficacy of second-line therapies remains modest. Therefore, early identification of patients likely to recur and treatment after recurrence remain critical unmet needs in the clinical care of bladder cancer patients. To address these deficits, a better understanding of the mechanisms of resistance to BCG-therapy is needed. The virtual update of the International Bladder Cancer Network (IBCN) on the biology of response to BCG focused on potential mechanisms and markers of resistance to intravesical BCG therapy. The insights from this meeting will be highlighted and put into context of previously reported mechanisms of resistance to BCG in this review.",
keywords = "Bacillus Calmette-Guerin (BCG), Bladder cancer, Immunotherapy",
author = "Reike, {M. J.} and Ingersoll, {M. A.} and M{\"u}ller, {D. C.} and Zuiverloon, {T. C.M.} and T. Strandgaard and Kamat, {A. M.} and Williams, {S. B.} and R. Seiler and T. Todenh{\"o}fer and L. Dyrskj{\o}t and R. Nawroth and P. Goebell and B. Schmitz-Dr{\"a}ger and Sfakianos, {J. P.} and J. Meeks and A. Horowitz and Black, {P. C.}",
note = "Funding Information: Ashish Kamat has been a consultant or on the advisory board of Arquer Diagnostics, Asieris, Astellas, Biological Dynamics, Bristol Myers Squibb (BMS), CG Oncology, H3 Biomedicine/Eisai, Engene, FerGene, Imagin Medical, Incyte DSMB, Janssen, Medac, Merck, Photocure, ProTara, Roche, Seattle Genetics, Sesen Bio, Theralase, TMC Innovation, US Biotest, Urogen Inc. and took part in clinical trials of Adolor, BMS, FKD Industries, Heat Biologics, Janssen, Merck, Photocure, Seattle Genetics and Taris. Stephen B. Williams has been on the advisory board for Janssen and consultant for Decipher Biosciences, Photocure, and Valar Labs. Lars Dyrskj{\o}t has sponsored research agreements with C2i, AstraZeneca, Natera, Photocure, and Ferring; has an advisory/consulting role at Ferring at UroGen; and is Chairman of the Board in BioXpedia A/S. Josh Meeks has been a consultant for Janssen, AstraZeneca, Merck, BMS, QED, Prokarium and UroGen with trials funded by Merck. John Sfakianos is a member of the advisory board of Urogen, Janssen and Pacific Edge. Amir Horowitz has been a consultant for Genentech, Takeda, and Immunorizon. He has received research funding from Zumutor Biologics. Peter C. Black has been a consultant for AbbVie, Astellas Pharma, EMD-Serono, Pfizer, Janssen Oncology, Bayer, Merck, Sanofi Canada, Biosyent, Ferring, Roche Canada, MDxHealth, AstraZeneca, UroGen Pharma, Bristol-Myers Squibb, Fergene, Prokarium, Protara, QED, STIMIT, Theralase, and Verity. He has received research funding from iProgen and shares a patent with Decipher Biosciences. Funding Information: Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), RE 4782/1-1. Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",
year = "2022",
doi = "10.1016/j.urolonc.2022.09.012",
language = "English (US)",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
}